Sanofi Press Releases

SNY 
$49.47
*  
0.29
0.58%
Get SNY Alerts
*Delayed - data as of Jul. 2, 2015  -  Find a broker to begin trading SNY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients
6/15/2015 8:00:00 AM - Business Wire
▼-0.26 % Price Change since this news event. The Volume Ratio is 1.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






FDA Advisory Committee Recommends Approval of Sanofi and Regeneron''s Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
6/9/2015 6:40:00 PM - PR Newswire
▼-2.68 % Price Change since this news event. The Volume Ratio is 1.19.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk
6/8/2015 2:16:00 PM - PR Newswire
▲0.04 % Price Change since this news event. The Volume Ratio is 1.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin
6/6/2015 10:00:00 AM - PR Newswire
▼-0.46 % Price Change since this news event. The Volume Ratio is 1.95.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sanofi Announces Study Program Evaluating Toujeo® in a Real-Life Setting
6/4/2015 8:00:00 AM - PR Newswire
▼-3.04 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Grants Breakthrough Therapy Designation for Genzyme’s Olipudase Alfa
6/4/2015 1:00:00 AM - Business Wire
▼-3.19 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Retrophin Agrees to Sell Priority Review Voucher to Sanofi
5/27/2015 8:00:00 AM - Business Wire


Genzyme Commemorates World MS Day with Awareness and Educational Events Globally
5/27/2015 6:00:00 AM - Business Wire
▲0.37 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC
5/26/2015 8:00:00 AM - Business Wire
▼-1.47 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Genzyme’s Announces Launch of Expression of Hope III Art Exhibit
5/20/2015 7:00:00 AM - Business Wire
▼-3.17 % Price Change since this news event. The Volume Ratio is 0.55.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga®
5/19/2015 8:00:00 AM - Business Wire
▼-2.31 % Price Change since this news event. The Volume Ratio is 1.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology
5/13/2015 7:00:00 AM - Business Wire
▼-0.26 % Price Change since this news event. The Volume Ratio is 0.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day














National Access Project for Cancer Testing Gains Momentum
4/21/2015 9:00:00 AM - Business Wire